Neuralink
Developing ultra-high bandwidth brain-machine interfaces to connect humans and computers.
Last verified:
What is Neuralink?
Neuralink develops implantable brain–machine interfaces (BMIs) designed to record and stimulate neural activity at high channel counts, with the stated goal of enabling people with paralysis and other neurological conditions to control computers and restore lost function. The company’s core offering centers on a compact implant (often referred to as the Link or N1 class device) that contains many electrodes on ultra-thin threads plus a wireless telemetry system to transmit signals through the skin to external devices. Neuralink also builds a robot to perform the delicate, minimally invasive implantation of those threads and an external software stack that decodes neural signals into commands for phones, cursors, or other assistive devices. The product is aimed primarily at clinical and therapeutic use for people with severe motor disabilities, while longer-term ambitions include expanding human communication bandwidth and enabling new human–computer capabilities.
Neuralink pricing
Pricing model: Freemium
The website does not list consumer pricing, free tiers, or paid subscription plans; Neuralink presents the implantable system and clinical-trial participation information without public pricing details, indicating that access and costs are currently handled via clinical programs and regulatory pathways rather than standard product tiers.
Neuralink pros
- Very high electrode channel count compared with existing clinical devices
- Fully implantable design with wireless telemetry through the skin
- Ultra-thin, flexible electrode threads intended to reduce tissue damage
- Robot-assisted implantation for precision and repeatability
- External software stack for real-time neural decoding and device control
- Targeted initially to people with paralysis and severe neurological deficits
- Aims to enable control of phones and computers without limb movement
- Focus on a patient-ready, take-home system rather than lab-only setups
- Rechargeable, compact external component for daily use
- Designed to record and stimulate for both sensing and therapeutic use
- Ambition to scale electrode counts by orders of magnitude over current devices
- In-house development of hardware, firmware, and surgical robotics for integration
- Clinical trial progress toward human implants and safety assessment
- Potential to restore communication for patients with ALS and similar conditions
- Company emphasis on safety, wireless operation, and at-home usability
Neuralink cons
- Implantation requires neurosurgery with associated surgical risks
- Long-term safety and biocompatibility data remain limited
- Unclear long-term device longevity and need for replacement surgeries
- High technical and regulatory hurdles before wide clinical availability
- Initial access limited to clinical-trial participants, not general consumers
- Potential privacy and security concerns around neural data telemetry
- Unknown cost and reimbursement pathway for patients and health systems
- Functionality demonstrated in early trials but not yet broadly validated
Frequently asked questions about Neuralink
What is Neuralink’s implant and what does it do?
Neuralink’s implant is a compact, fully implantable device with many microelectrodes on flexible threads that sits on or in the skull and wirelessly transmits recorded neural signals to external systems; it is designed to both record neural activity and deliver stimulation, enabling signal decoding for cursor/phone control and potential therapeutic stimulation.
Who is the implant intended for initially?
Neuralink’s initial target users are people with paralysis or severe motor impairments (for example due to spinal cord injury, ALS, or stroke) who could benefit from a high-bandwidth interface to control computers and assistive technologies.
How is the device implanted?
The company uses a purpose-built surgical robot to place ultra-thin electrode threads into targeted brain regions through a minimally invasive procedure, aiming for precision placement while reducing manual surgical variability and tissue trauma.
Is the device wireless and wearable at home?
Yes; Neuralink describes a fully implantable system with wireless telemetry that enables patients to use the device at home with an external communication unit that receives signals through the skin and connects to phones or computers.
Can the implant both read and stimulate brain activity?
Neuralink’s system is designed to both record high-resolution neural signals and deliver stimulation, which supports applications ranging from neural decoding for control to therapeutic stimulation approaches similar in intent to deep brain stimulation.
Has Neuralink implanted humans yet?
Neuralink has progressed to human clinical trials and has reported human implantations as part of regulatory-approved safety assessments; the website emphasizes ongoing trials and iterative evaluation rather than broad commercial availability.
What are the main safety considerations?
Key safety concerns highlighted include surgical risks from implantation, short- and long-term biocompatibility of implanted threads, device reliability over time, infection prevention, and rigorous monitoring within clinical trials to assess adverse events and functional outcomes.
How many electrodes does the implant support?
Neuralink’s described implants aim to support substantially higher electrode counts than legacy clinical devices, with designs discussed in public materials targeting on the order of hundreds to over a thousand channels to increase information bandwidth.
Will Neuralink be available to the general public soon?
No—Neuralink presents itself as operating through clinical trials and regulatory pathways, so broad public availability depends on successful long-term safety and efficacy results and subsequent regulatory approvals, rather than immediate consumer release.
Does Neuralink publish pricing or reimbursement information?
No; the website does not provide pricing, subscription tiers, or reimbursement details and indicates that access is currently via clinical programs and regulatory approvals rather than through published commercial plans.